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Abstract: Formazan-based colorimetric cytotoxicity assays, such as the MTT assay, are typically
used to assess cell viability with only metabolically active cells reducing tetrazolium salts into the
formazans, which is then quantified by absorbance. Fluorescence offers several advantages compared
to colorimetric assays and would enable techniques such as flow cytometry and confocal microscopy
to be used for analysis. Here, fluorescent formazans 10, 11 and 12, and their corresponding
tetrazolium salts 13, 16 and 24, respectively, were synthesised by incorporation of a known
fluorophore backbone (coumarin, fluorescein and rhodol) with disruption of the conjugated system
preventing or reducing fluorescence of the tetrazolium salts. The tetrazolium moiety was able to
quench the fluorescence of the incorporated fluorescein and O-methyl rhodol, whereas with the
coumarin-based tetrazolium salt the fluorescence was only quenched under acidic conditions. These
tetrazolium salts were successfully reduced to the fluorescent formazans with cells and offer a step
forward in the development of fluorescent cytotoxicity assays.
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1. INTRODUCTION
Formazans were first described at the end of the 19th century but were largely ignored until the 1940’s
when their potential as localisation stains in living systems was reported [1,2]. Interest in formazans
increased after the discovery that the addition of triphenyltetrazolium chloride 1 to cells resulted in
reduction of the pale yellow 1 to the deeply coloured triphenylformazan 2 (Figure 1A) [3]. This
discovery resulted in the development of the formazan-based colorimetric cytotoxicity assay
(typically called an MTT assay) using 3-(4,5-dimethylthiazoyl-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT) 3 with the dye only reduced by cells that are metabolically active to give 3-(4,5-
dimethylthiazoyl-2-yl)-2,5-diphenylformazan 4 (Figure 1A) [4]. The mechanism of MTT reduction is
still debated, but it is clear that it is reduced intracellularly. MTT was originally thought to be up-
taken by endocytosis and reduced in perinuclear vesicles, such as lysosomes and endosomes [5];
however, MTT has since been used to measure membrane potentials, which is only possible if the
tetrazolium salt can permeate the cell membrane [6]. Inside cells, the tetrazolium salt 3 is believed to
be reduced (in an NADH/NADPH dependent manner) to give the strongly coloured formazan 4,
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which is readily quantified by absorbance and can be used as a cellular viability marker [7]. However,
the reduction product 4 is not soluble in aqueous media, requiring an solubilisation process, which
complicates the assay and introduces error.
Figure 1. (A) Triphenyltetrazolium chloride 1 and MTT 3 are reduced in vitro to coloured formazans
2 and 4, respectively. (B) Tetrazolium salts 5, 6, and 7 used in the 2nd generation cytotoxicity assays,
which result in the formation of water-soluble formazans.
Sulphonated tetrazolium salts, including 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-
carboxanilide 5 and 3-(4-5-dimethylthiazoyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfonyl)-2H-
tetrazolium salt 6, were developed to increase the aqueous solubility of the formazans, eliminating the
need for a solubilisation step in the assay (Figure 1B) [8]. However, their cellular uptake is limited
and the reduction is not as efficient as for MTT 2 and requires the use of an intermediate electron
acceptor (such as phenazine methosulfate) to promote reduction [9, 10]. Based on these, another class
of water soluble tetrazolium salts (WSTs) was developed, including 4-(3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio)-1,3-benzene disulfonate salt (WST-1) 7 (Figure 1B) [11], and other
WSTs similar to 7 have become available for use in cytotoxicity assays. Although the tetrazolium salt
is reduced to a highly water-soluble formazan, the mechanism of reduction is significantly different to
the reduction of MTT, with reduction by membrane based enzymes at the cell surface.. Additionally,
these WSTs may be reduced by other species in the media such as glutathione [12].
Fluorescence offers several advantages compared to colorimetric assays, such as sensitivity.
Fluorescent cytotoxicity assay would enable techniques such as flow cytometry and confocal
microscopy to be used for analysis. The most frequently used fluorescent assay is the Alamar blue (or
resazurin) assay [13], which has been used to test for bacterial contamination in milk since the 1950’s.
In the Alamar blue assay, resazurin is reduced by oxidoreductases to generate the strongly fluorescent
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resorufin  (λEx/λEm 570/590 nm); however, resorufin can be further reduced to a non-fluorescent
dihydroresorufin, which in cytotoxicity assays can significantly underestimate cell viability. Given the
utility of the MTT assay and the benefits of fluorescence-based detection it is surprising that there is
not currently a fluorescent formazan-based cytotoxicity assay for mammalian cells. 3-Cyano-1,5-
ditolyl tetrazolium chloride 8, which upon reduction gives a fluorescent formazan 9 (λEx/λEm 488/630
nm) (Figure 2), and has been used as a viability assay for anaerobic bacteria [14] but cannot be used
with eukaryotic cells as it cannot cross the eukaryotic cell membrane [15]. Although 9 is commonly
used as an indicator of bacterial viability, several studies have raised questions about the accuracy of
the assay as different species give different responses and 8 may also be reduced by chemical
additives in the culture media [16, 17].
Here, we present the design and synthesis of fluorescent formazans and their corresponding
tetrazolium salts.
Figure 2. Non-fluorescent 3-cyano-1,5-ditolyl tetrazolium chloride 8 is reduced by anaerobic bacteria
into fluorescent 3-cyano-1,5-ditolylformazan 9 (λEx/λEm 488/630 nm) [14]. The two methyl groups in
the phenyl rings of 9 are essential for the fluorescence as the structurally similar 3-cyano-1,5-
diphenylformazan is non-fluorescent.
2. RESULTS AND DISCUSSION
It is difficult to predict whether or not a molecule will be fluorescent; however, planarity and extended
conjugation are common features in fluorescent molecules [18], but not all highly conjugated
molecules are fluorescent (for example MTT 3 and the corresponding formazan 4 are not fluorescent).
Here, we targeted fluorescent formazans using three known fluorescent cores (coumarin, fluorescein
and rhodol). The hypothesis was that a “switch-on” fluorescent assay, similar to the MTT assay,
would be possible by introducing a fluorophore into the formazan, with disruption of the conjugated
system preventing or reducing fluorescence, i.e., the positive charge of the corresponding tetrazolium
salt (Figure 3).
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Figure 3. Design of fluorescent formazans 10, 11 and 12, incorporating coumarin, fluorescein or
rhodol-based fluorophores, for cytotoxicity assays. The fluorescence was postulated to be quenched
(“turned-off”) in the corresponding tetrazolium salts, proving a “switch-on” mechanism for the
fluorescence detection upon cellular reduction.
Figure 3. Design of fluorescent formazans 10, 11 and 12, incorporating coumarin, fluorescein or
rhodol-based fluorophores, for cytotoxicity assays. The fluorescence was postulated to be quenched
(“turned-off”) in the corresponding tetrazolium salts, proving a “switch-on” mechanism for the
fluorescence detection upon cellular reduction.
2.1. Synthesis of fluorophore-based formazans and tetrazolium salts
The first target molecule was 10, which can be considered to be a formazan attached to the
fluorophore 7-amino-4-methyl coumarin (AMC), which has an available aniline group for
incorporation into the formazan core. Coumarins are of particular interest as they are known to have
high quantum yields and retain high fluorescence even following large structural changes [19, 20].
The corresponding coumarin-based tetrazolium salt 13 was synthesised in three steps (Scheme 1). 7-
Amino-4-methylcoumarin [20] was diazotised using a solid-supported nitrite resin [21] and 14 was
isolated as the p-toluenesulfonic acid salt. Benzaldehyde phenylhydrazone 15 [22] was added to the
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diazonium salt 14 in 2M HCl to give the coumarin–formazan 10 in 62% yield. Oxidition with N-
bromosuccinimide (NBS) gave the corresponding tetrazolium 13 in 69% yield.
Scheme 1. (a) Amberlyst A26 based nitrite resin, AcOH, p-TsOH, 0 °C to rt, 1 h, (64%) (b) 2M HCl,
NaNO2, benzaldehyde phenylhydrazone 15, pyridine, DMF, 4 h (62%); (c) NBS, EtOAc, 50 °C, 20 h
(69%).
The “fluorescein-based” tetrazolium salt 16 was synthesised in five steps from fluorescein.
Fluorescein monotriflate 17 was synthesised by microwave heating fluorescein and N-phenyl-
bis(trifluoromethanesulfonimide) (PhN(OTf)2) in the presence of K2CO3 [23], followed by a Suzuki
coupling with 4-aminophenyl boronic acid pinacol ester under thermal conditions to give 18 in 71%
yield (Scheme 2) [24]. Diazotisation of 18 and subsequent treatment with benzaldehyde
phenylhydrazone 15 afforded the desired fluorescein–formazan 11 in 29% yield, with oxidation using
NBS giving the tetrazolium salt 16 in 86% yield.
Scheme 2. Synthesis of fluorescein–formazan 11 and the corresponding fluorescein–tetrazolium salt
16. a) PhN(OTf)2, K2CO3, DMF, 20 min, mw 80 °C (48%); b) 4-aminophenyl boronic acid
pinacolester, Pd(OAc)2, PPh3, Na2CO3, toluene/EtOH (1:1), 80 °C, 22 h (71%), (c) 2M HCl, NaNO2,
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H2O, 0 °C, 90 min; d) benzaldehyde phenylhydrazone 15, pyridine, DMF, 0 °C to rt, 18 h (38%); (e)
NBS, EtOAc, 50 oC, 24 h (86%).
To allow regioselective incorporation of the formazan moiety into a rhodol-based fluorophore
(compound 12), mono O-methyl fluorescein 19 was synthesised [25]. Fluorescein was first treated
with methyl iodide (with concomitant methyl ether and methyl ester formation) and subsequent
hydrolysis with LiOH gave 19 in 71% yield. Conversion of the phenol moiety in 19 to the
corresponding aniline 22 was achieved by the method of Grimm [26], i.e., triflation (compound 20),
followed by Buchwald-Hartwig amination with tert-butyl carbamate (compound 21) and deprotection
to afford O-methyl rhodol 22 as a TFA salt in 56% overall yield over three steps (Scheme 3). O-
Methyl rhodol 22 was treated with sodium nitrite, to generate the diazonium salt 23, which was then
treated with diphenylhydrazone 15 to furnish the desired formazan 12 in moderate 25% yield (Scheme
3). NBS oxidation gave the corresponding tetrazolium salt 24, which precipitated from the reaction
mixture and was isolated by filtration in 83% yield.
Scheme 3. Synthesis of 12 and the corresponding tetrazolium salt 24. a) NaOH, MeOH, 2 h; b) MeI,
DMF, 24 h; c) LiOH, MeOH, 100 °C, 24 h (71%); d) PhN(OTf)2, DIPEA, DMF, 2 h (78%); e) t-butyl
carbamate, Pd(dbba)3, xantphos, CsCO3, dioxane, N2 atm, 18 h (75%); f) 20%TFA in DCM, 2 h
(95%); g) NaNO2, HCl, 0 °C, 1 h; h) 15, pyridine, DMF, 0 °C to rt, 18 h (25%); i) NBS, EtOAc, 50
°C, 16 h (83%).
2.2. Optical properties of the tetrazolium salts and formazans
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The optical properties of the fluorophore-based formazans and their corresponding tetrazolium salts
were analysed and compared to the optical properties of the “parent fluorophores” (Table 1). The
formazans 10, 11 and 12 all showed fluorescence emission between 420 and 470 nm (in EtOH)
(Figure 3). The emission wavelength of the formazans was not dependent on the emission wavelength
of the parent fluorophore.
Table 1.Optical properties of the synthesised formazans and tetrazolium salts, and their “parent”
fluorophores (in EtOH unless otherwise stated).
Compound λEx (nm) λEm (nm)
AMC 350 426 0.78
10 370 468 0.11
13 350 432 0.10
13 pH 4[a] 390 432 0.04
18 480 520 0.26
11 370 445 0.19
16 370 434[b] –[c]
22 428 523 0.74
12 350 428 0.18
24 350 n/f[d] –
[a] recorded in acidified PBS/MeOH [b] weakly fluorescent, 4.8-fold difference in emission intensity
compared to 11 [c] could not be determined [d] non-fluorescent.
Wavelength (nm)
RF
U
300 400 500 600 700
0
1.010 7
2.010 7
3.010 7
4.010 7
5.010 7
6.010 7
2.15 ex 370 nm
2.24 ex 350 nm
AMC-F 2.3 ex 370 nm
445 nm
468 nm428 nm
Figure 3. Comparison of fluorescence emission of formazans 10 (λex/em 370/468 nm), 11 (λex/em
370/445 nm), and 12 (λex/em 350/428 nm) in EtOH (recorded at 100 mM).
Coumarin-based formazan 10 showed a 42 nm red shift compared to AMC (ESI, Figure S1), possibly
due to the increased conjugation gained from the formazan structure; however, the quantum yield of
10 was lower than that of reported for AMC (Φ 0.11 versus 0.78) [27]. The coumarin-based
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tetrazolium salt 13 remained fluorescent in EtOH (λEm 432 nm, Φ 0.10) with a 36 nm blue-shift in
fluorescence compared to 10 (4-fold difference between the emission intensities (λEx 350 nm) of 13
and 10). However, under aqueous acidic conditions (1:1 MeOH/PBS with 1% HCl), 13 was almost
non-fluorescent whereas formazan 10 retained its fluorescent properties (60-fold difference in
emission intensities) (Figure 3A). The difference in fluorescent intensity between 13 and the reduced
form 10 could thus be exploited in a cytotoxicity assay where the tetrazolium salt is reduced to a
fluorescent formazan and extracted in acidic PBS/MeOH (similar to that used for the MTT assay).
Aniline modified fluorescein 18 had a fluorescence emission maximum at 520 nm (λEm 480 nm) and a
quantum yield of 0.26. When this moiety was incorporated into formazan 11, the emission was blue-
shifted by 75 nm to 445 nm (Φ 0.19) (ESI, Figure S2). The corresponding tetrazolium salt 16 was
considerably less fluorescent than the formazan counterpart 11 (xx-fold difference in the emission
intensity) (Figure 3B). Similarly with O-methyl rhodol-based formazan 12 (λEx/λEm 370/427 nm, Φ 
0.18) the emission was blue-shifted by 96 nm compared to parent fluorohore O-methyl rhodol 22 (λEm
523 nm) (ESI, Figure S3). The tetrazolium salt 24 was non-fluorescent (λEx 350 nm) showing that as
postulated the positive charge of the tetrazolium salt is able to quench the fluorescence (Figure 3C).
Wavelength (nm)
RF
U
400 500 600 700
0
1.0105
2.0105
AMC-F 2.3 ex 370 nm
AMC-T 2.1 ex 390 nm
468 nm
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Wavelength (nm)
RF
U
300 400 500 600 700
0
1.010 7
2.010 7
3.010 7 2.16 ex 370 nm
2.15 ex370 nm445 nm
434 nm
Wavelength (nm)
RF
U
400 500 600 700
0
2.010 7
4.010 7
6.010 7 2.24 ex 350 nm
2.25 ex 350 nm
428 nm
Figure 3. (A) Fluorescence emission of coumarin-based formazan 10 (λex/λem 370/468 nm) and the
corresponding tetrazolium salt 13 (λex 390) in acidic PBS–MeOH (1:1). (B) Fluorescence emission of
fluorescein–formazan 11 (2.15) emission (λex/em 370/445 nm) and its tetrazolium salt 16 (2.16)
emission (λex/em 370/434 nm in EtOH; (C) Fluorescence emission of O-Methylrholdol-based formazan
12 (2.24) emission (λex\em 350/428 nm) compared to its tetrazolium salt 24 (2.25) (λex 350 nm)
recorded in EtOH. All compounds were measured at 100 mM.
3. Cell-based fluorescent analysis
Tetrazolium salts 13, 16 and 24 (50 μM) were incubated with HeLa cells for 20 hours to allow the 
reduction to the formazans 10, 11 and 12, respectively. Formation of non-soluble crystals was
observed on the surface of the cells (Figure 4A–B). The formazan crystals were isolated, solubilised
in EtOH, and the fluorescence was measured with the expected emission observed with all the
samples (Figure 4C, ESI, Figure S4). For the coumarin-based tetrazolium salt 13 the cell-based
reduction into 10 was also confirmed by mass spectrometry of both the supernatant and cell lysate,
which confirmed that 13 had been taken up by the cells. Coumarin-based 10 and 13 showed notably
cytotoxicity in a MTT assay at 100 μM, whereas with formazans 11 and 12 were non-cytotoxic up to
10 μM (tetrazolium salts 16 and 24 were not toxic at 50 μM) (ESI Figure S5). 
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Wavelength (nm)
RF
U
400 500 600 700
0
1.010 7
2.010 7 Recovered AMC-F 2.3 ex 370 nm468 nm
Figure 4. A) HeLa cells immediately after the addition of tetrazolium salt 10 (10 μM). B) Cells 
following 28 hours incubation showing black formazan 13 crystals (× 100 magnification). C)
Recovered AMC-F 2.3; HeLa cells, AMC-T 2.1, Fluorescent emission of recovered 10 after 24 hour
incubation of 13 (50 μM) with HeLa. Supernatant was removed and the formazan crystals were 
collected by centrifugation and dried. Fluorescence was measured in EtOH.
4. CONCLUSIONS
The fluorescent formazans 10, 11 and 12, and their corresponding tetrazolium salts 13, 16 and 24,
respectively, were synthesised by incorporation of a known fluorophore. The large structural changes
to the core structure did not affect the in vitro activity of the tetrazolium salts, which were
successfully reduced to the fluorescent formazans with cells. The emission wavelengths of the
fluorophore conjugated formazans were not directly dependent on the parent fluorophores, i.e., the
fluorescence of 10 was red shifted compared to AMC whereas both fluorescein-based 11 and O-
methyl rhodol-based 12 were blue shifted to the green region and were lower than the emission of 10.
The tetrazolium moiety was able to quench the fluorescence of incorporated fluorescein and O-methyl
rhodol (compounds 16 and 24, respectively), whereas with the coumarin-based 13 the fluorescence
was only quenched in acidic medium, which is typically used in MTT assay.
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EXPERIMENTAL
All chemicals were purchased from commercial suppliers and used as received. Microwave assisted
heating was done in a Biotage Initiator at 2.45 GHz at a fixed temperature. 1H and 13C NMR
spectroscopy were recorded on an automated Bruker AVA400 (400 and 100 MHz, respectively) or
Bruker AVA500 (500 and 126 MHz, respectively) spectrometer and the chemical shifts are quoted in
relative to the solvent. ESI-MS analysis was recorded on an Agilent 1100 system with mass spectra
acquired on a VG platform single Quadrupole MS-electrospray positive (ES)+ or negative (ES)-
mode. HRMS were acquired using a Bruker MicroToF II in electropositive (ES)+ or electronegative
mode (ES)-, or acquired using a Finnigan MAT 900 XLP high-resolution double-focusing mass
spectrometer. FT-IR spectra were recorded on a Bruker Tensor 27 with a golden gate accessory for
solid samples. Melting points were measured on a Gallenkampf melting point apparatus.
UV absorbance analysis was conducted on an Agilent 8453 spectrophotometer using 100% solvent as
blank. Fluorescence emission was measured using a Jobin Yvon SPEX Fluoro Max fluorometer with
Data Max version 2.20 software in EtOH unless otherwise indicated. Quantum yields were calculated
by comparison to either fluorescein (in 0.1 M NaOH) or harmaline (0.005 M H2SO4) standard.
Absorbance and fluorescence measurements for quantum yields were acquired with Synergy plate
reader loaded with Gen5 (1.1) software using Costar 96-well, flat-bottomed clear plates. Dyes were
dissolved in EtOH and quantum yield was calculated using Equation 1
Φ = Φref.·
IୱI୰ୣ ୤. ∙ A୰ୣ ୤.Aୱ ∙ ηୱη୰ୣ ୤.
Equation 1. Calculation of quantum yield (Φ); Φref. fluorescein: 0.92, harmaline: 0.32, Is= integrated
fluorescence of the sample, Iref.= integrated fluorescence of the reference, Aref.= absorbance of reference, As =
absorbance of the sample, ηs = refractive index of the sample solvent, ηref.= refractive index of the reference
sample (0.1 M NaOH and 0.005 M Na2SO4 η= 1.36, EtOH η= 1.36).
7-Amino-4-methylcoumarin diazonium (14)
7-Amino-4-methyl coumarin (0.2 g, 1.0 mmol) was suspended in AcOH (10 mL) and cooled to 0 °C.
Amberlyst A26 based nitrite resin [91] (0.7 g, 3.0 mmol) was added portion-wise over 20 min,
followed by p-toluenesulfonic acid (0.6 g, 3.0 mmol). The mixture was warmed to room temperature
and stirred for 1 h. The mixture was filtered and the resulting amber filtrate was poured into cold
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diethyl ether (100 mL) and the resulting precipitate was collected and washed with cold ether (30 mL)
to give 14 as a beige solid (0.2 g, 64%). mp 135–140°C; IR νmax (cm-1) 2284 (N≡N), 1728 (C=O); 1H
NMR (d6-DMSO, 400 MHz) δ 8.77 (1H, d, J = 2.0 Hz), 8.61 (1H, dd, J = 8.8, 2.0 Hz), 8.29 (1H, d, J
= 8.7 Hz), 7.46 (2H, d, J = 8.0 Hz), 7.10 (2H, d, J = 7.9 Hz), 6.88 (1H, d, J =1.4 Hz), 2.51 (3H, s),
2.29 (3H, s); 13C NMR (100 MHz, d6-DMSO) δ 157.7, 151.7, 151.2, 145.5, 137.5, 129.5, 128.2, 
128.0, 127.4, 125.4, 120.4, 120.2, 116.9, 22.7, 17.9; MS (ESI) m/z 381.1 [M+Na]+
3-(7-Amino-4-methylcoumarin)-2,5-phenyl formazan (10)
Benzaldehyde phenylhydrazone 15 (78 mg, 0.4 mmol) in DMF (0.5 mL) and pyridine (0.1
mL), was cooled to 0 °C, and 7-amino-4-methylcoumarin diazonium salt 14 (144 mg, 0.4
mmol) in cold 2M HCl (0.2 mL) was added drop-wise. The mixture was stirred at room
temperature for 16 h. Upon completion, the solution was poured into water (5 mL) and conc.
HCl was added until the solution was acidic (pH 1). The resulting precipitate was filtered,
washed with water (10 mL), and dried in vacuo. Purification by column chromatography
(50% EtOAc in hexane) gave 10 as a dark purple powder (68 mg, 62%). mp 204–209 °C; IR
νmax (cm−1) 3052 (NH), 1721 (C=O), 1607 (N=N), 1507 (C=N), 1219 (CN); 1H NMR (500
MHz, CDCl3) δ 15.00 (1H, s), 8.12 (2H, d, J = 7.4 Hz), 7.90 (2H, d, J = 7.5 Hz), 7.58−7.55 
(3H, m), 7.52−7.46 (4H, m), 7.39 (1H, t, J = 7.3 Hz), 7.33 (1H, dd, J = 8.6, 2.0 Hz), 6.19 (1H,
d, J = 1.1 Hz), 2.43 (3H, d, J = 1.1 Hz); 13C NMR (126 MHz, CDCl3) δ 161.0, 155.1, 152.2, 
151.3, 147.6, 142.1, 136.5, 131.3, 129.6, 128.5, 128.4, 126.4, 125.8, 121.8, 116.3, 113.0,
112.3, 103.1, 18.7; HRMS (ESI) [M-H]- m/z calculated for C23H17O2N4 381.1352, obtained
381.0924; UV/VIS (EtOH) λmax 387 nm; λex/em 370/468 nm; Φ 0.11. 
3-(7-amino-4-methyl coumarin)-2,5-phenyl tetrazolium bromide (13)
Formazan 10 (60 mg, 0.16 mmol) was suspended in EtOAc (0.68 mL) and heated to 50 °C. To this N-
bromosuccinimide (74 mg, 0.20 mmol) in EtOAc (0.48 mL) was added and the mixture was stirred at
50 °C for 12 hours. After cooling to room temperature, the cream precipitate was collected by
filtration and dissolved in DCM (3 mL). The solution was washed with aqueous sodium
tetrafluoroborate (5 mL), dried over Na2SO4, and evaporated in vacuo to give 13 as a white powder
(42 mg, 69%). No purification was required. mp 234−239 °C;; IR νmax (cm-1) 1721 (C=O), 1457
(C=N); 1H NMR (400 MHz, d6-DMSO) δ 8.18 (2H, d, J = 7.1 Hz), 8.01 (1H, dd, J = 8.6, 2.0 Hz),
7.95 (2H, d, J = 7.7 Hz), 7.81 (1H, d, J = 2.0 Hz), 7.70 (1H, t, J = 8.6 Hz), 7.63 (1H, t, J = 7.6 Hz),
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7.60–7.54 (5H, m), 6.38 (1H, d, J = 1.2 Hz), 2.42 (3H, d, J = 1.1 Hz); 13C NMR (126 MHz, d6-
DMSO) δ 161.2, 155.3, 152.4, 151.5, 147.8, 142.4, 136.8, 130.9, 129.2 (2 ×), 128.2 (2 ×), 128.0, 
125.9 (2 ×), 125.4, 121.5 (2 ×), 116.6, 112.60, 111.9, 102.7, 18.9; ESI-MS [M]+ m/z 381.1; HRMS
(ES) [M]+ m/z calculated for C23H17O2N4+ 381.1352 obtained 381.1069; UV/VIS (EtOH) λmax 297
nm; λex/em 350/432 nm; Φ 0.10 (EtOH) and 0.04 (in acidic PBS/MeOH). 
3-(Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,3'-hydroxy-6'-(4-amino phenyl)-4,5-
phenylformazan (11)
Sodium nitrite (41 mg, 0.58 mmol) was added to 11 (185 mg, 0.45 mmol) in 2M HCl (3 mL) at 0 °C
and stirred for 90 minutes. This solution was added drop-wise to a solution of diphenylhydrazone 15
(96 mg, 0.9 mmol) in DMF (1.2 mL) and pyridine (0.6 mL) at 0 °C. The reaction was stirred at room
temperature for 22 hours. The reaction mixture was poured into water (10 mL) and acidified with 2M
HCl to pH 1, the precipitate was collected by filtration, and dried at 40 °C in a vacuum oven for 24
hours. Purification by column chromatography (30% EtOAc in hexane) gave a 16 as dark red powder
(104 mg, 38%). mp171−175 °C; IR νmax (cm-1) 3373 (OH), 3032 (NH), 1728 (C=O); 1H NMR; (500
MHz, DMSO) δ 14.11 (1H, s), 10.10 (1H, s), 8.04 (1H, d, J = 7.6 Hz), 7.99 (2H, d, J = 7.2 Hz),
7.93−7.88 (6H, m), 7.82 (1H, dt, J = 7.5, 1.0 Hz), 7.75 (2H, dd, J = 8.1, 4.6 Hz), 7.56−7.53 (2H, m), 
7.51−7.47 (3H, m), 7.39 (2H, d, J = 7.3 Hz), 7.34 (1H, d, J = 7.6 Hz), 6.85 (1H, d, J = 8.3 Hz), 6.75
(1H, d, J = 2.3 Hz), 6.64 (1H, d, J = 8.7 Hz), 6.59 (1H, dd, J = 8.7, 2.3 Hz); 13C NMR (126 MHz, d6-
DMSO) δ 169.1, 152.4, 151.7, 151.0, 148.3,146.9, 142.3, 141.9, 136.4, 135.7, 135.6, 130.2, 129.7 (2 
×), 129.4, 128.8, 128.7 (2 ×), 128.6, 128.2 (2 ×), 128.1, 126.7 (2 ×), 125.7, 124.7, 124.0, 122.1, 121.0,
120.0 (2 ×), 119.2 (2 ×), 117.7, 114.3, 112.8, 109.1, 102.2, 91.7; HRMS (ESI) [M+H]+ m/z calculated
for C39H27O4N4 m/z 615.2023 obtained 615.2024; UV/VIS (EtOH) λmax 300, 500 nm; λex/em 370/445
nm; Φ 0.19. 
3-(Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one,3'-hydroxy-6'-(4-amino phenyl)-4,5-
phenyltetrazolium bromide (16)
Fluorescein formazan 16 (11.3 mg, 0.02 mmol) was suspended in EtOAc (0.3 mL) and heated to 50
°C. N-bromosuccinimide (10 mg, 0.05 mmol) in EtOAc (0.3 mL) was added, and the mixture stirred
at 50 °C for 12 hours. The precipitate was collected by filtration to give 16 (9.7 mg, 86%). No
purification was required. mp 171−175 °C; IR νmax (cm-1) 3359 (OH), 3034 (CH), 1758 (C=O), 1596
(C=N); 1H NMR (400 MHz, MeOD) δ 8.39 (2H, d, J = 7.1 Hz′), 8.10 (1H, d, J = 7.3 Hz ), 8.05 (2H,
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d, J = 8.6 Hz), 7.88–7.87 (3H, m), 7.85–7.81 (5H, m), 7.77 (2H, d, J = 7.3 Hz), 7.76–7.72 (5H, m),
7.51 (1H, d, J = 8.6 Hz), 7.30 (1H, d, J J = 8.0 Hz), 6.98 (1H, d, J = 8.0 Hz), 6.91 (1H, s); 13C NMR
(126 MHz, MeOD) δ 161.3, 160.8, 157.9, 156.5, 151.8, 151.5, 145.9, 145.2, 145.1, 141.0, 139.9, 
139.8 (2 ×), 138.6, 138.0, 137.9 (2 ×), 137.8, 137.5, 137.5 (2 ×), 135.9 (2 ×), 134.3, 133.7, 131.7,
129.2 (2 ×), 129.1, 128.5, 128.4 (2 ×), 128.3, 127.3, 123.9, 123.8, 122.2, 118.9, 118.8; ESI-MS m/z
613.3 [M]+; UV/VIS (EtOH) λmax 300 nm; λex/em 370/432 Φ 0.01. 
1-(Methylrhodol)-3,5-diphenylformazan (12)
Sodium nitrite (12 mg, 0.17 mmol) in water (300 μL) was added to O-methylrhodol 22 (50 mg, 0.15
mmol) in 2M HCl (0.75 mL) at 0 °C and stirred for 60 minutes. This solution was added to a solution
of diphenylhydrazone 15 (30 mg, 0.15 mmol) in cold DMF (1.75 mL) and pyridine (0.35 mL), and the
reaction brought to room temperature. The reaction was stirred for 22 hours and then poured into
water (10 mL). 2M HCl was added until the solution became acidic (pH 1), the resultant crystals were
collected by filtration and washed with water (20 mL). The solid was dried in a vacuum oven at 40 °C
to give dark red crystals (20 mg, 25%). No purification required. mp 201–204 °C; IR νmax (cm-1)
3061 (NH), 1760 (C=O), 1614 (C=N), 1505 (NH), 1218 (CN); 1H NMR (500 MHz, CDCl3) δ 15.15 
(1H, s,), 8.16 (2H, d, J = 7.3 Hz), 8.07 (1H, d, J = 7.6 Hz), 7.86 (2H, d, J = 7.6 Hz), 7.71 (1H, t, J =
6.5), 7.66 (1H, t, J = 7.4 Hz ′), 7.59–7.52 (3H, m), 7.51–7.43 (3H, m), 7.41 (1H, t, J = 7.3 Hz), 7.22
(1H, d, J = 7.5 Hz), 7.12 (1H, dd, J = 8.5, 1.9 Hz), 6.86–6.79 (2H, m), 6.73 (1H, d, J = 8.8 Hz), 6.65
(1H, dd, J = 8.8, 2.4 Hz), 3.85 (3H, s)CH3); 13C NMR (126 MHz, CDCl3) δ 169.5,161.4, 153.2, 
152.5, 152.4, 150.5, 147.1, 141.6, 136.9, 135.1, 130.3, 129.8, 129.5 (2 ×), 129.2, 129.0, 128.4 (2 ×),
128.0, 126.6, 126.1 (2 ×), 125.1, 123.9, 121.1 (2 ×), 115.2, 112.7, 111.8, 111.0, 103.8, 100.9, 83.0,
55.6; HRMS (ES) m/z [M+H]+ calculated for C34H25N4O4 553.1870 obtained 553.1726; UV/VIS
(EtOH) λmax 298 & 483 nm;; λex/em 350/428 nm; Φ 0.18. 
1-Methoxyrhodol-3,5-diphenyl tetrazolium salt (24)
Formazan 12 (20 mg, 0.03 mmol) was suspended in EtOAc (0.6 mL) and warmed to 50 °C. To this N-
bromosuccinimide (16 mg, 0.09 mmol, 2.5 eq.) in EtOAc (0.4 mL) was added, and the mixture was
stirred at 50oC for 16 hours. The precipitate was collected by filtration, to afford a cream powder (15
mg, 83%). No purification was required. mp 142−147 °C; IR νmax (cm-1) 1695 (C=O), 1102 (COC);
1H NMR (500 MHz, CDCl3) δ 8.17 (2H, d, J = 7.4 Hz), 8.04 (1H, d, J = 7.6 Hz), 7.89 (1H, d, J =
2.2 Hz), 7.82 (2H, d, J = 7.9 Hz), 7.75 (1H, t, J = 7.4 Hz) 7.67−7.64 (2H, m), 7.61–7.49 (5H, m), 7.33 
(1H, dd, J = 8.6, 2.1 Hz), 7.18 (1H, d, J = 7.6 Hz), 6.92 (1H, d, J = 8.6 Hz, H8), 6.79 (1H, d, J = 1.9
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Hz), 6.74–6.66 (2H, m), 3.85 (3H, d, J = 7.2 Hz); 13C NMR (126 MHz, CDCl3) δ 176.9, 168.8, 166.0, 
161.8, 152.1, 151.7, 151.6, 135.8, 134.1, 134.0, 133.2, 133.0, 130.5 (2 ×), 130.1, 129.4 (2 ×), 128.8,
128.0 (2 ×), 126.2 (2 ×), 125.8, 125.4, 124.9, 124.0, 122.9, 120.4, 116.0, 113.1, 109.8, 101.0, 81.1,
55.7; HRMS (ES) m/z [M]+ calculated for C34H23N4O4+ 555.1714 obtained 555.3324.
Reduction of tetrazolium salt in cells   
HEK293T cells were cultured in T75 culture flasks in DMEM media, supplemented with 10 % FBS, 4
mM glutamine, and 100 units/mL of penicillin/streptomycin, and grown to 50–60% confluence.
Tetrazolium salts 13, 16, or 24 (0.5 mM in 1 mL DMSO) were added to phenol red free DMEM
media (10 mL) to give a final concentration of 50 μM. DMEM cell media was removed and replaced 
with DMEM with tetrazolium salts and the cells were incubated at 37 °C for 24 hours. The media was
removed and the cells washed with PBS three times. The PBS and media were combined and
centrifuged (1200 rpm) for 15 minutes. The supernatant was removed leaving the formazan residue,
which was dried at 40 °C in a vacuum oven, and then dissolved in EtOH (5 mL) and fluorescence was
recorded. The samples were also analysed by mass spectrometry to confirm presence of the formazans
10–12.
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